The stock of Assembly Biosciences Inc. (ASMB) has gone up by 6.49% for the week, with a 8.25% rise in the past month and a -8.53% drop in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are 7.59% for ASMB. The simple moving average for the past 20 days is 7.24% for ASMB’s stock, with a -14.45% simple moving average for the past 200 days.
Is It Worth Investing in Assembly Biosciences Inc. (NASDAQ: ASMB) Right Now?
while the 36-month beta value is 0.74.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Assembly Biosciences Inc. (ASMB) is $3.00, which is $2.0 above the current market price. The public float for ASMB is 49.58M, and currently, short sellers hold a 0.25% ratio of that floaft. The average trading volume of ASMB on September 19, 2023 was 90.68K shares.
ASMB) stock’s latest price update
The stock price of Assembly Biosciences Inc. (NASDAQ: ASMB) has jumped by 9.60 compared to previous close of 0.91. Despite this, the company has seen a gain of 6.49% in its stock price over the last five trading days. GlobeNewsWire reported 2023-05-23 that SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
Analysts’ Opinion of ASMB
Many brokerage firms have already submitted their reports for ASMB stocks, with H.C. Wainwright repeating the rating for ASMB by listing it as a “Neutral.” The predicted price for ASMB in the upcoming period, according to H.C. Wainwright is $3.50 based on the research report published on September 13, 2021 of the previous year 2021.
ASMB Trading at -1.97% from the 50-Day Moving Average
After a stumble in the market that brought ASMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.07% of loss for the given period.
Volatility was left at 7.59%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares surge +7.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.69% lower at present.
During the last 5 trading sessions, ASMB rose by +6.49%, which changed the moving average for the period of 200-days by -25.04% in comparison to the 20-day moving average, which settled at $0.9330. In addition, Assembly Biosciences Inc. saw -23.31% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ASMB starting from Okazaki Jason A, who sale 11,827 shares at the price of $1.09 back on Aug 02. After this action, Okazaki Jason A now owns 164,786 shares of Assembly Biosciences Inc., valued at $12,867 using the latest closing price.
Delaney William E IV, the Chief Scientific Officer of Assembly Biosciences Inc., sale 9,461 shares at $1.09 during a trade that took place back on Aug 02, which means that Delaney William E IV is holding 142,744 shares at $10,293 based on the most recent closing price.
Stock Fundamentals for ASMB
The total capital return value is set at -71.13, while invested capital returns managed to touch -73.01. Equity return is now at value -104.90, with -87.30 for asset returns.
Based on Assembly Biosciences Inc. (ASMB), the company’s capital structure generated 4.19 points at debt to equity in total, while total debt to capital is 4.02. Total debt to assets is 3.38, with long-term debt to equity ratio resting at 0.12. Finally, the long-term debt to capital ratio is 0.12.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.95.
In a nutshell, Assembly Biosciences Inc. (ASMB) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.